Share on StockTwits

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) EVP Suzanne Sawochka Hooper sold 1,185 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $133.15, for a total value of $157,782.75. Following the completion of the transaction, the executive vice president now directly owns 51,804 shares in the company, valued at approximately $6,897,703. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of research firms have recently commented on JAZZ. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, August 7th. They now have a $150.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday, August 6th. Finally, analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday, August 6th. Six analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $174.05.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 8.81% on Wednesday, hitting $144.23. 2,021,895 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52-week low of $77.25 and a 52-week high of $176.60. The stock’s 50-day moving average is $145.4 and its 200-day moving average is $144.8. The company has a market cap of $8.686 billion and a P/E ratio of 97.97.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter last year, the company posted $1.43 earnings per share. Jazz Pharmaceuticals plc -‘s revenue was up 39.8% compared to the same quarter last year. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.18 earnings per share for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.